Eli Lilly at GIPR
As of the edition of 20 October 2026, Eli Lilly is on route B at GIPR (gastric inhibitory polypeptide receptor), position 12 of 2,016 on that route, with a score of 0.780.
Sources: ClinicalTrials.gov, approval registers, ChEMBL, FDA Orange Book and Purple Book.
Route and score
Route B Score 0.780
Biology proven in humans0.96
How much the company cares0.91
Room, and a reason to act now0.54
Each part runs from 0 to 1; 0.5 is neutral, and an unknown fact counts as neutral.
What moved the score
Proof in humans at the target+0.294
Took its own drug far in human testing+0.225
Active at the target or its disease area recently+0.183
Trials at the target more often meet than miss their main endpoint+0.167
Few other companies active at the target+0.087
The company’s own follow-on drug-0.044
Why its own drug stopped0.000
The facts that decided the route
- Does the company have its own row at this target, rather than being counted under a drug that acts on many targets? The company has its own row at this target As of 20 October 2026.
- Has the company not been dissolved without a successor? The company still exists or has a successor As of 24 September 2026.
- Does the company have a marketed drug at this target? The company has a marketed drug at this target As of 13 May 2022.
- Does the company have no approved follow-on drug at this target? The company has no approved follow-on of its own As of 13 May 2022.
- Is the protein the drug acts on identified, and not only a complex it belongs to? The protein the drug acts on is on record, not only its complex As of 20 October 2026.
- Does a source say which of the drug's many targets it is designed for? The target the drug is designed for is established As of 20 October 2026.
The drugs
| Drug | Status | Furthest phase | Trials | US protection |
|---|---|---|---|---|
| Tirzepatide | Marketed | Phase 4 | 195 | Patent ends: 14 June 2039 |
| Retatrutide | Active | Phase 3 | 34 | none listed |
| LY3537021 | Active | Phase 2 | 3 | none listed |
The trials behind it
| Trial | Drug | Phase | Status | Years | Participants | Result |
|---|---|---|---|---|---|---|
| NCT06901349 | Tirzepatide | Phase 2 | Withdrawn | 2025 to 2025 | 0 | No results posted |
| The registry records: “Study terminated for strategic business reasons” | ||||||
| NCT07817875 | Tirzepatide | Phase 3 | Not yet recruiting | 2026 to 2032 | 150 | No results posted |
| NCT07803744 | Tirzepatide | Phase 1 | Recruiting | 2026 to 2026 | 18 | No results posted |
| NCT07438444 | Tirzepatide | Phase 4 | Active not recruiting | 2026 to 2027 | 344 | No results posted |
| NCT07357415 | Retatrutide | Phase 3 | Active not recruiting | 2026 to 2028 | 600 | No results posted |
| NCT07299084 | Tirzepatide | Phase 1 | Active not recruiting | 2026 to 2026 | 40 | No results posted |
| NCT07169851 | LY3537021 | Phase 2 | Recruiting | 2025 to 2027 | 204 | No results posted |
| NCT07247084 | Tirzepatide | Phase 4 | Recruiting | 2025 to 2032 | 3,000 | No results posted |
| NCT07232719 | Retatrutide | Phase 3 | Active not recruiting | 2025 to 2027 | 250 | No results posted |
| NCT07165028 | Retatrutide | Phase 3 | Recruiting | 2025 to 2032 | 4,500 | No results posted |
| NCT06937086 | Tirzepatide | Phase 3 | Recruiting | 2025 to 2028 | 350 | No results posted |
| NCT06937099 | Tirzepatide | Phase 3 | Recruiting | 2025 to 2028 | 290 | No results posted |